NASDAQ:FGEN - FibroGen Stock Price, Forecast & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FGEN stock has decreased by 1.0% and is now trading at $35.03. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) released its quarterly earnings data on Monday, March, 2nd. The biopharmaceutical company reported ($1.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.53. The biopharmaceutical company had revenue of $7.97 million for the quarter, compared to the consensus estimate of $40.32 million. FibroGen had a negative net margin of 30.00% and a negative return on equity of 13.35%. FibroGen's quarterly revenue was down 92.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.23 earnings per share. View FibroGen's earnings history.

5 brokers have issued 1-year price targets for FibroGen's stock. Their forecasts range from $40.00 to $72.00. On average, they anticipate FibroGen's stock price to reach $52.00 in the next year. This suggests a possible upside of 48.4% from the stock's current price. View analysts' price targets for FibroGen.

Headlines about FGEN stock have been trending very negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. FibroGen earned a coverage optimism score of -3.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutFibroGen.

FibroGen saw a decline in short interest in February. As of February 28th, there was short interest totaling 5,390,000 shares, a decline of 7.7% from the February 13th total of 5,840,000 shares. Based on an average daily trading volume, of 612,100 shares, the days-to-cover ratio is currently 8.8 days. Currently, 6.7% of the company's stock are short sold. View FibroGen's Current Options Chain.

Some companies that are related to FibroGen include GALAPAGOS NV/S (GLPG), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Beigene (BGNE), Mylan (MYL), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Allergan (AGN).

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $35.03.

FibroGen has a market capitalization of $3.08 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe. View additional information about FibroGen.

The official website for FibroGen is http://www.fibrogen.com/.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]